Introduction {#s1}
============

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of death globally ([@B4]). Clinical screenings for CRC include fecal occult blood test, colonoscopy screening and conventional tumor biomarkers ([@B23]; [@B10]). However, almost 90% of deaths might be preventable if CRC patients were diagnosed at an early stage ([@B29]). Therefore, sensitive diagnostic biomarkers for early detection of CRC are urgently needed.

Exosomes are extracellular vesicles, which contain multiple proteins, lipids, DNA and different RNA species ([@B27]). Increasing findings have indicated that exosome-delivered RNAs involve in the occurrence and progress of cancers, which also involved in epithelial--mesenchymal transition ([@B35]), angiogenesis ([@B31]), premetastatic niche ([@B16]), immune response and therapeutic resistance ([@B36]). Furthermore, isolation of exosomes from accessible bodily fluids (blood, urine, saliva, etc.) made it possible to apply exosomes in clinical diagnosis ([@B28]; [@B26]; [@B32]; [@B33]). Some exosome-delivered circRNAs, such as circPTGR1, have been reported that it is stably present in exosomes and play an essential role in hepatocellular carcinoma development ([@B34]; [@B38]).

Circular RNAs (circRNAs) are a kind of single-stranded covalently closed RNAs ([@B8]), which were initially identified as splicing-associated noise in the early 1990s and formed by backsplicing process of pre-mRNA ([@B5]; [@B11]). Recently, a number of studies reported that circRNAs were closely associated with the initiation and development of cancers, including CRC ([@B24]; [@B12]; [@B20]). In fact, circRNAs are more stable than linear RNAs due to their special loop structure which lack of 5'-3' polarity and polyadenylate tail. This could prevent from RNase R degradation or RNA exonuclease digestion ([@B30]). Hence, stable circRNAs are rich in peripheral blood and has potential as biomarkers of diseases ([@B7]; [@B34]).

In this study, we screened exosomal hsa-circ-0004771 as a candidate for potential diagnostic biomarker of CRC by database analysis, and explored its expression in exosome of sera, CRC tissues and cells. Our results revealed that exosomal hsa-circ-0004771 was significantly up-regulated in sera of CRC patients with significant diagnostic efficacy, it could offer new opportunities for potential diagnosis targeting colorectal cancer.

Materials and Methods {#s2}
=====================

Study Population {#s2_1}
----------------

A total of 135 CRC patients, 35 patients with benign intestinal diseases (BIDs) and 45 healthy controls (HCs) were enrolled from Nanjing First Hospital affiliated to Nanjing Medical University. CRC patients were confirmed by histopathological analysis of the surgical resection tissues. All pre-operation serum samples were collected from patients with treatment naïve. The HCs were recruited from disease-free healthy volunteers and subjects for body check. Written informed consents were obtained from each participant, and the study protocol was approved by the Research and Ethical Committee of Nanjing First Hospital. The information about clinicopathological characteristics of all participants was retrieved from medical records and questionnaires, which was summarized in [**Table 1**](#T1){ref-type="table"}.

###### 

Clinical characteristics of the participants.

  Parameters                    Discovery Phase   Validation Phase   Exploration Phase                                      
  ----------------------------- ----------------- ------------------ ------------------- ----------- ----------- ---------- ----------
  **Age, years (mean ± SD)**    58 ± 7.6          62 ± 9.3           60 ± 10.8           56 ± 10.2   60 ± 13.3   59 ± 8.7   61 ± 4.8
  **Gender (M/F)**              5/5               5/5                19/16               21/14       76/34       4/1        8/2
  **Drinking**                  4                 5                  17                  27          71          5          6
  **BID**                                                                                                                   
  **Acute/Chronic Enteritis**   \\                \\                 \\                  19          \\          \\         \\
  **Intestinal Polyps**         \\                \\                 \\                  6           \\          \\         \\
  **Intestinal Obstruction**    \\                \\                 \\                  8           \\          \\         \\
  **Crohn's Disease**           \\                \\                 \\                  2           \\          \\         \\
  **TNM stage**                                                                                                             
  **I**                         \\                2                  \\                  \\          29          2          6
  **II**                        \\                4                  \\                  \\          41          3          3
  **III**                       \\                3                  \\                  \\          27          \\         1
  **IV**                        \\                1                  \\                  \\          13          \\         0

CRC, colorectal cancer; HC, healthy control; BID, benign intestinal diseases; ANT, adjacent normal tissue; M, male; F, female.

Study Design {#s2_2}
------------

As shown in [**Figure 1**](#f1){ref-type="fig"}, our study was conducted in three phases, discovery phase, validation phase, and exploration phase. In the discovery phase, we selected exosomal hsa-circ-0004771 as a target gene of CRC based on the integrated analysis of two Gene Expression Omnibus (GEO) datasets and verification in the age-matched HCs and BC patients by using qRT-PCR. In the validation phase, the diagnostic value of exosomal hsa-circ-0004771 was assessed by its relative expressions among 180 subjects, including 70 stage I/II CRC patients, 40 stage III/IV CRC patients, 35 patients with BIDs, and 35 HCs). Finally, in the exploration phase, the origin of exosomal hsa-circ-0004771 in serum of CRC patients was explored in tumor tissue and CRC cell lines.

![Flow chart of the study design. ROC, receiver operating characteristic; qRT-PCR, quantitative real-time polymerase chain reaction; HC, healthy control; BID, benign intestinal diseases; CRC, colorectal cancer; ANT, adjacent normal tissue.](fgene-10-01096-g001){#f1}

Cell Culture {#s2_3}
------------

Human colorectal mucosal epithelial cell (FHC) and CRC cell lines (HCT-116 and SW-480) were obtained from American Type Culture Collection. FHC, HCT-8 and HCT-116 cells were cultured in RPMI-1640 with 10% fetal bovine serum (FBS) and other cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM). All of the cell lines are bathed with 10% FBS and 1% penicillin/streptomycin (P/S) solution and incubated in an incubator containing 5% CO~2~ at 37°C.

Isolation of Exosomes {#s2_4}
---------------------

Exosomes were isolated from serum and medium samples using Invitrogen^™^ Total Exosome Isolation Kits (4478359 and 4478360) (Invitrogen, NYC, USA) according to the manufacturer's protocol. For serum samples, serum was collected from venous blood after centrifugation at 2,000 × *g* for 20 min and subsequently mixed with the exosome isolation reagent. The mixture was centrifuged at 15,000 × *g*, 4°C for 2 min after standing for 30 min, then the supernatant was removed to obtain exosome precipitation. For cell lines, the culture media were collected for exosome isolation from culture plates with cells being cultivated for 24 h or 48 h, and then the exosomes were isolated according to the manufacturer's protocol.

Extraction of RNAs and qRT-PCR {#s2_5}
------------------------------

Total RNA was extracted from exosomes, cells and tissues respectively, by using TRIzol reagent (Invitrogen, NYC, USA). Thereafter, 1 ug total RNA was added to a final volume of 20 µl mixed reagent for reverse transcription. Then different expression of hsa-circ-0004771 from exosomes, cells and tissues real-time PCR (qRT-PCR) was conducted in triplicate with specific primers of hsa-circRNAs, which were chemically synthesized and validated in RiboBio Company (RiboBio, Guangdong, China). The sequence of circ-00047771: former primer, AGTTGCTCCAATGACAGAGTTACC; reverse primer,CCTCCTTCAGTCAAGTGTGCATC.

The PCR was conducted on ABI 7500 real-time PCR system (Applied Biosystems, CA, USA) used SYBR Green (Takara, China) The relative expression levels of circRNAs were calculated by the 2\^^--ΔΔCt^ method.

Transmission Electron Microscopy Analysis {#s2_6}
-----------------------------------------

Isolated exosomes were re-suspended in 100 µl phosphate-buffered saline (pH 7.4) and fixed in 50 µl glutaraldehyde. Subsequently, fixed exosomes were dropped onto a formvar-carbon coated grid, left to dry at room temperature for 5 min, excess liquid was removed and then stained with phosphotungstic acidoxalate for 1 min. Then, the grid was further dried at room temperature for 10 min and visualized on Tecnai G2 F20 transmission electron microscope (TEM) (FEI, United States) at 185 kV.

Western Blot {#s2_7}
------------

To test the expression of exosome specific protein CD63 and TSG101, the whole proteins were extracted from serum of subjects, and culture media of cell lines by using the Whole protein extraction kit (KGP2100). The protein concentration was measured by bicinchoninic acid (BCA) kit (KGPBCA) (KeyGEN BioTECH, China). After immunoblotting, the proteins attached to polyvinylidene fluoride (PVDF) membrane were incubated overnight at 4°C with specific antibodies, and subsequently incubated with HPR-labeled secondary antibodies. Finally, the membrane was exposed with chemiluminescent agents.

Bioinformatics Analysis {#s2_8}
-----------------------

We searched the GEO database with the following keywords restricting, namely ("circRNA" OR "circRNAs" OR "Circular RNAs"), ("colorectal carcinoma" OR "colorectal cancer" OR "colorectal neoplasm" OR "colorectal tumor" OR "CRC") and ("exosome" OR "exosomes"). The differentially expressed circRNAs in GEO datasets were analyzed by using online tool GEO2R.

Statistical Analyses {#s2_9}
--------------------

Chi-square test was used to compare the clinicopathological features of each group and the Student's t test was conducted to examine differences in expression of circRNAs. Receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were constructed to assess the diagnostic performance of hsa-circ-0004771, and the corresponding cutoff points of the ROC curve were determined by the Youden's Index. The sensitivity, specificity and 95% confidence intervals (CIs) were calculated using the binary regression model ([@B13]). All of the data were analyzed by IBM SPSS version 19.0 (IBM Corp, NYC, USA) and the graphs were generated by GraphPad Prism 8 software (GraphPad Software, CA, USA) and R language. The P value \< 0.05 is considered statistically significant.

Results {#s3}
=======

Exosomal hsa-circ-0004771 Was Significantly Up-Regulated in Sera of CRC Patients With Remarkable Diagnostic Value {#s3_1}
-----------------------------------------------------------------------------------------------------------------

After analysis of difference and abundance expression of circRNAs in GSE100206 (n = 32) and GSE100063 (n = 12) datasets, 59 circulating exosomal circRNAs with fold change ≥1.5 and P value \<0.05 were identified as differentially expressed circRNAs (DEcircRNAs) ([**Figure 2A**](#f2){ref-type="fig"}). We selected hsa-circ-0004771 for the study as the expression of hsa-circ-0004771 was the most abundant among top 10 up-regulated ones ([**Figure 2B**](#f2){ref-type="fig"}, [**Supplement Table 1**](#SM1){ref-type="supplementary-material"}). ROC analysis showed that the diagnostic value of circulating exosomal hsa-circ-0004771 to differentiate CRC patients from HCs was remarkably high (AUC = 0.90) ([**Figure 2C**](#f2){ref-type="fig"}). To further confirm the results, we enrolled 10 CRC patients and 10 healthy controls, and the isolated exosomes from clinical serum samples were verified through TEM ([**Figure 2D**](#f2){ref-type="fig"}), western blot ([**Figure 2E**](#f2){ref-type="fig"}) and nanosight particle tracking analysis ([**Figure 2F**](#f2){ref-type="fig"}). GAPDH was used as an internal reference of exosomal circRNAs in peripheral blood because the expression of exosomal GAPDH in serum had no difference between CRC patients and HCs and did not obviously change during the incubation time (4, 8, 24 h) at room temperatures ([**Figure 2G**](#f2){ref-type="fig"}). Up-regulated expression was consistently observed in serum of CRC patients compared to HCs by qRT-PCR ([**Figure 2H**](#f2){ref-type="fig"}). ROC analysis showed that the AUC of circulating exosomal hsa-circ-0004771 was 0.92 to differentiate CRC patients from HCs ([**Figure 2I**](#f2){ref-type="fig"}).

![Identification and validation of up-regulated exosomal hsa-circ-0004771 in peripheral blood of CRC patients.**(A)** Heat maps of DEcircRNAs of analysis of GSE100206 and GSE100063. **(B)** Expression of DEcircRNAs in GEO datasets. **(C)** ROC analysis of hsa-circ-0004771 in GEO datasets (*P* \< 0.001). **(D**--**F)** TEM, western blot analysis and nanosight particle tracking of peripheral blood exosomes. **(G)** The expression value of exosomal GAPDH in serum of CRC patients and HCs at different standing times. **(H)** qRT-PCR analysis of hsa-circ-0004771 expressions in peripheral blood exosomes of CRC patients (n = 10) and HCs (n = 10). **(I)** ROC analysis of circulating exosomal hsa-circ-0004771 to differentiate CRC patients from HCs (*P* \< 0.001). DEcircRNAs, differentially expressed circRNAs; ROC, receiver operating characteristic; TEM, transmission electron microscope; qRT-PCR, quantitative real-time polymerase chain reaction; CRC, colorectal cancer; HC, healthy control.](fgene-10-01096-g002){#f2}

Validating the Expression and Diagnostic Value of Circulating Exosomal hsa-circ-0004771 in an Independent Cohort {#s3_2}
----------------------------------------------------------------------------------------------------------------

To validate the dysregulated expression of circulating exosomal hsa-circ-0004771, serum samples of 110 CRC patients, 35 patients with BID, and 35 HCs, were tested. First, we observed that there was no significant difference in the expression of serum exosomal circ-0004771 between HCs and CRC patients, and the corresponding AUC was 0.59 with the sensitivity of 54.29% and specificity of 68.57% (*P* = 0.190) ([**Figure 3A**](#f3){ref-type="fig"}). Then, we compared the expression circulating exosomal hsa-circ-0004771 between stage I/II CRC patients and HCs. As shown in [**Figure 3B**](#f3){ref-type="fig"}, exosomal hsa-circ-0004771 was also significantly elevated in the serum of stage I/II CRC patients. The AUC was 0.86 (95%CI, 0.785--0.933) to discriminate stage I/II CRC patients from HCs with the sensitivity of 81.43% and specificity of 80% (*P* \< 0.001). When compared with HCs, the expression of exosomal hsa-circ-0004771 in serum was significantly up-regulated in CRC patients with all TNM stages. The AUC of circulating exosomal hsa-circ-0004771 to differentiate CRC patients with all stages from HCs was 0.88 (95%CI, 0.815--0.940) with the sensitivity of 80.91% and specificity of 82.86% (*P* \< 0.001) ([**Figure 3C**](#f3){ref-type="fig"}). Subsequently, we found that the expressions of exosomal hsa-circ-0004771 in serum were significantly up-regulated in stage I/II CRC patients to differentiate patients with BIDs from stage I/II CRC patients was 0.81 (95%CI, 0.728--0.900) with the sensitivity of 81.43% and specificity of 74.29% (*P* \< 0.001) ([**Figure 3D**](#f3){ref-type="fig"}). Finally, the Chi-square test revealed that expression of circulating exosomal hsa-circ-0004771 was significantly correlated with TNM stage (*P* = 0.017) and distant metastasis (*P* = 0.004) ([**Table 2**](#T2){ref-type="table"}).

![Dysregulated circulating exosomal hsa-circ-0004771 serves as a promising diagnostic biomarker for CRC. **(A**--**C)** qRT-PCR and AUC analysis of hsa-circ-0004771 expression in patients with BID (n = 35), stage I/II CRC patients (n = 70) and CRC patients (all stage) (n = 110) compared with HCs (n = 35), respectively. **(D)** qRT-PCR and AUC analysis of hsa-circ-0004771 expression in patients with BID (n = 35) compared with stage I/II CRC patients (*P* \< 0.001). qRT-PCR, quantitative real-time polymerase chain reaction; CRC, colorectal cancer; HC, healthy control; BID, benign intestinal diseases; ROC, receiver operating characteristic.](fgene-10-01096-g003){#f3}

###### 

Correlations between hsa-circ-0004771 expression and clinicopathological features of CRC patients in serum exosomes.

  -----------------------------------------------------------------------------------------------
  Characteristics            Number\    Expression of hsa-circ-0004771   P value^a^   
                             of Cases                                                 
  -------------------------- ---------- -------------------------------- ------------ -----------
  **Age, years**             110                                                      

  **\< 50**                  36         20                               16           0.416

  **≥50**                    74         35                               39           

  **Gender**                                                                          

  **Male**                   72         38                               34           0.423

  **Female**                 38         17                               21           

  **TNM stage**                                                                       

  **I--II**                  70         41                               29           **0.017**

  **III--IV**                40         14                               26           

  **Lymphatic Metastasis**                                                            

  **N0**                     87         46                               41           0.241

  **N1 + N2**                23         9                                14           

  **Distant Metastasis**                                                              

  **M0**                     88         50                               38           **0.004**

  **M1**                     22         5                                17           
  -----------------------------------------------------------------------------------------------

Statistical significant results (in bold) (P \< 0.05).

Elevated Circulating Exosomal hsa-circ-0004771 in CRC Patients was Tumor-Derived {#s3_3}
--------------------------------------------------------------------------------

Several studies reported cancer cells may release circRNAs in the cargo of exosomes into the peripheral blood ([@B14]; [@B19]; [@B22]). To explore the source of up-regulated exosomal hsa-circ-0004771, we firstly examined the results of high-throughput sequencing using three paired CRC tissues and adjacent normal tissues (ANTs). Unexpectedly, we found that hsa-circ-0004771 was significantly down-regulated in CRC tissues ([**Figure 4A**](#f4){ref-type="fig"}), and qRT-PCR verified hsa-circ-0004771 was significantly down-regulated in CRC tissues and cells ([**Figures 4B--C**](#f4){ref-type="fig"}). To explore the origin of circulating exosomal hsa-circ-0004771, we firstly examined ten pairs of serum specimens collected from CRC patients before and after surgery operation. The result shown that the expression of circulating exosomal hsa-circ-0004771 was significantly decreased after operation ([**Figure 4D**](#f4){ref-type="fig"}), suggesting increased expression of exosomal hsa-circ-0004771 may be tumor-derived. Meanwhile, the results of relative expression of exosomal hsa-circ-0004771, which were also verified by TEM, nanosight particle tracking analysis and western blot ([**Figures 4E--G**](#f4){ref-type="fig"}). In cultured media of CRC cells (HCT-116 and SW-480) revealed that the increased exosomal hsa-circ-0004771 expression was depended on the cell numbers and culture time ([**Figures 4H--I**](#f4){ref-type="fig"}). In addition, we applied GW4869, a known blocker for exosomes, to inhibit the exosomes secretion. We found that the expression of exosomal hsa-circ-0004771 was significantly down-regulated in cultured media, but not significantly changed in the CRC cells ([**Figures 4J--K**](#f4){ref-type="fig"}).

![Elevated expression of circulating exosomal hsa-circ-0004771 was tumor-derived. **(A)** Heat map of differentially expressed circRNAs in CRC tissues and ANTs by high-throughput sequencing. Red in the two plots denotes up-regulation; blue denotes down-regulation. **(B)** qRT-PCR analysis of hsa-circ-0004771 expression in five pairs of CRC tissues and ANTs. **(C)** qRT-PCR analysis of hsa-circ-0004771 expression in colorectal mucosal epithelial cell (FHC) and CRC cells. **(D)** qRT-PCR analysis of hsa-circ-0004771 expression in 10 pairs of preoperative serum samples and corresponding postoperative samples. **(E**--**G)** TEM, and western blot analysis nanosight particle tracking of exosomes in cell cultured media (HCT-116 and SW-480). **(H** and **I)** qRT-PCR analysis of hsa-circ-0004771 expression in cultured media with different time points and cell numbers. **(J** and **K)** qRT-PCR analysis of hsa-circ-0004771 expression in CRC cells and corresponding cultured media after treated with GW4869. CRC, colorectal cancer; ANT, adjacent normal tissue; qRT-PCR, quantitative real-time polymerase chain reaction; TEM, transmission electron microscope.](fgene-10-01096-g004){#f4}

Discussion {#s4}
==========

In this study, we first sought to determine circulating exosomal hsa-circ-0004771 was significantly up-regulated in the sera of CRC patients and showed a high diagnostic value for CRC patients. Subsequently, elevated exosomal hsa-circ-0004771 in serum of CRC patients was demonstrated to be tumor-derived.

With the advent of bioinformatics analysis and high-throughput sequencing technology, functional circRNAs have been extensively elucidated. CircRNAs are stable and abundant in cells due to their special covalently closed cyclic structure. They also being reported as key regulators in biological progression of cancers ([@B3]). Up to now, rising evidence reveals that circRNAs are closely associated with angiogenesis, tumor microenvironment and metastasis of various cancers ([@B40]; [@B9]; [@B21]). For example, Bahn et al. reported that in human saliva, 422 circRNAs might participate in inflammatory and chemotaxis responses and regulate microenvironment of cancer ([@B2]). In CRC, circCCDC66 sponged miRNA-33b and miR-93 to protect the MYC mRNA so that tumor proliferation, migration, and metastasis were activated in both *in vitro* and *in vivo* ([@B17]). However, the role of hsa-circ-0004771 (circNRIP1) and its diagnostic value in cancer remain poorly characterized. So far, hsa-circ-0004771 was only shown as an oncogene in gastric cancer (GC), knockdown of hsa-circ-0004771 blocked malignant tumor phenotype of GC cells ([@B39]). Our study revealed that exosomal hsa-circ-0004771 was significantly up-regulated in sera of CRC patients and the increased expression of exosomal hsa-circ-0004771 may be tumor-derived. However, the biological role of hsa-circ-0004771 in CRC still needed further investigation.

In recent years, exosome have been widely studied as an important regulatory node for the intercellular interaction of cells ([@B6]; [@B18]), and the exosomes derived from tumor cells could package circRNAs and be released into the circulation system ([@B1]). Moreover, circulating circRNAs in exosome as biomarkers of diseases has aroused great attention ([@B15]; [@B25]). We discovered exosomal hsa-circ-0004771 was significantly up-regulated in the sera of CRC patients and identified as a novel potential biomarker for the early diagnosis of CRC patients based on the public data uploaded into the GEO database. Interestingly, we found hsa-circ-0004771 was down-regulated in exosome of CRC cells and CRC tissues, which may be consistent with the idea of Lasda et al. who supposed that the active transport of circRNAs to exosomes may be a mechanism for circRNAs clearance ([@B22]). CircRNAs, which are enriched and stable in cells, may be bound to RNA binding proteins and transported to exosomes ([@B14]; [@B37]), but the actual sorting mechanism of circRNAs into exosomes needed to be further investigated.

In conclusion, we demonstrated that the exosomal hsa-circ-0004771 was significantly up-regulated in CRC patients' sera. Circulating exosomal hsa-circ-0004771 could serve as a novel potential biomarker for early diagnosis of CRC.
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